Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, thalidomide, and dexamethasone in newly diagnosed Waldenstrom's macroglobulinemia
NCT03335098Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Waldenstrom macroglobulinemia (WM), Lymphoplasmacytic Lymphoma (LPL), sponsored by Seoul National University Hospital. Status: unknown.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT03335098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335098.